Literature DB >> 8704218

Active involvement of catalase during hemolytic crises of favism.

G F Gaetani1, M Rolfo, S Arena, R Mangerini, G F Meloni, A M Ferraris.   

Abstract

The endemic occurrence of favism in certain Mediterranean regions provided an investigative opportunity for testing in vivo the validity of claims as to the role of catalase in protecting human erythrocytes against peroxidative injury. Reduced activity of catalase was found in the erythrocytes of six boys who were deficient in erythrocytic glucose-6-phosphate dehydrogenase (G6PD) and who were studied while suffering hemolysis after ingesting fava beans. Activity of catalase was further reduced when their red blood cells were incubated with aminotriazole. In contrast, minimal reduction of catalase activity was found, both with and without incubation with aminotriazole, in erythrocytes of a G6PD-deficient boy who had ingested fava beans 7 days earlier and in erythrocytes of seven G6PD-deficient men with a past history of favism. These results confirmed earlier studies in vitro indicating that catalase is a major disposer of hydrogen peroxide in human erythrocytes and, like the glutathione peroxidase/reductase pathway, is dependent on the availability of reduced nicotinamide adenine dinucleotide phosphate (NADPH). The effect of divicine on purified catalase and on the catalase of intact G6PD-deficient erythrocytes was similar to the previously demonstrated effect on catalase of a known system for generating hydrogen peroxide. This effect of divicine strengthens earlier arguments that divicine is the toxic peroxidative component of fava beans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704218

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  PharmGKB summary: methylene blue pathway.

Authors:  Ellen M McDonagh; José M Bautista; Ilan Youngster; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-09       Impact factor: 2.089

Review 2.  PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

Authors:  Ellen M McDonagh; Caroline F Thorn; John T Callaghan; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-09       Impact factor: 2.089

3.  Predicting the Kinetic Properties Associated with Redox Imbalance after Oxidative Crisis in G6PD-Deficient Erythrocytes: A Simulation Study.

Authors:  Hanae Shimo; Taiko Nishino; Masaru Tomita
Journal:  Adv Hematol       Date:  2011-09-28

4.  Detailed functional analysis of two clinical glucose-6-phosphate dehydrogenase (G6PD) variants, G6PDViangchan and G6PDViangchan+Mahidol: Decreased stability and catalytic efficiency contribute to the clinical phenotype.

Authors:  Usa Boonyuen; Kamonwan Chamchoy; Thitiluck Swangsri; Naowarat Saralamba; Nicholas P J Day; Mallika Imwong
Journal:  Mol Genet Metab       Date:  2016-03-25       Impact factor: 4.797

5.  Data mining and pathway analysis of glucose-6-phosphate dehydrogenase with natural language processing.

Authors:  Long Chen; Chunhua Zhang; Yanling Wang; Yuqian Li; Qiaoqiao Han; Huixin Yang; Yuechun Zhu
Journal:  Mol Med Rep       Date:  2017-06-15       Impact factor: 2.952

6.  Markers of oxidative stress in umbilical cord blood from G6PD deficient African newborns.

Authors:  Paul S Stadem; Megan V Hilgers; Derrick Bengo; Sarah E Cusick; Susan Ndidde; Tina M Slusher; Troy C Lund
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

7.  A trade off between catalytic activity and protein stability determines the clinical manifestations of glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Authors:  Usa Boonyuen; Kamonwan Chamchoy; Thitiluck Swangsri; Thanyaphorn Junkree; Nicholas P J Day; Nicholas J White; Mallika Imwong
Journal:  Int J Biol Macromol       Date:  2017-06-03       Impact factor: 6.953

8.  Antioxidant vitamins and glucose-6-phosphate dehydrogenase deficiency in full-term neonates.

Authors:  Khalid K Abdul-Razzak; Enaam M Almomany; Mohamad K Nusier; Ahmad D Obediat; Ahmad M Salim
Journal:  Ger Med Sci       Date:  2008-09-24

9.  Is there a need for neonatal screening of glucose-6-phosphate dehydrogenase deficiency in Canada?

Authors:  Aaron Leong
Journal:  Mcgill J Med       Date:  2007-01

Review 10.  G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications.

Authors:  Lucio Luzzatto; Elisa Seneca
Journal:  Br J Haematol       Date:  2013-12-28       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.